Prof. Mei X. Wu Profile

Prof. Mei X. Wu

Professor at Harvard Medical School

SPIE Involvement:

Conference Program Committee | Conference Chair | Editor | Author

Proceedings Article | 13 March 2024 Presentation

Rapid disassembly of bacterial biofilms by a blue light-ferric modality

Yongli Li, Mei Wu, Zhengkun Zhang, Yan Dong

Proceedings Volume PC12822, PC128220L (2024) https://doi.org/10.1117/12.3004474

KEYWORDS: Biofilms, Ions, Matrices, Ion irradiation, Bacteria, Transmission electron microscopy, Tolerancing, Temperature metrology, Resistance, Polymers

Read Abstract +

Proceedings Article | 17 March 2023 Presentation

Photobiomodulation enhances the endurance of anaerobic exercise

Mei Wu, Prabhat Upadhyay, Min Yan

Proceedings Volume PC12362, PC1236208 (2023) https://doi.org/10.1117/12.2653354

KEYWORDS: Hypoxia, Glucose, Blood, Tissues, Switches, In vitro testing

Read Abstract +

Proceedings Article | 17 March 2023 Presentation

To distinguish bacterial and viral infections with a microneedle array-immunosensor

Mei Wu, Zuan-Tao Lin

Proceedings Volume PC12358, PC1235805 (2023) https://doi.org/10.1117/12.2651382

KEYWORDS: Blood, Proteins, Inflammation, Reliability

Read Abstract +

Proceedings Article | 5 March 2021 Presentation

LLL promotes engraftment of human umbilical cord blood-derived hematopoietic stem and progenitor cells

Mei Wu, Jingke Yang

Proceedings Volume 11628, 1162809 (2021) https://doi.org/10.1117/12.2583150

KEYWORDS: Light emitting diodes, Transplantation, Stem cells, Proteins, Oxygen, Hydrogen, Blood

Read Abstract +

Proceedings Article | 5 March 2021 Presentation

Bacteria-specific phototoxic reactions triggered by blue light and edible carvacrol

Mei Wu, Min Lu

Proceedings Volume 11626, 116260R (2021) https://doi.org/10.1117/12.2583127

KEYWORDS: Bacteria, Wound healing, Skin, Resistance, Photolysis, Oxygen, Molecules

Read Abstract +

Proceedings Article | 7 March 2019 Presentation + Paper

Potentials of noninvasive low-level laser therapy for neonatal thrombocytopenia

Min Lu, PeiYu Li, Qi Zhang, Yu Yang, Shuguang Wen, Mei Wu

Proceedings Volume 10861, 1086109 (2019) https://doi.org/10.1117/12.2507053

KEYWORDS: Liver, Bone, Fetus, Laser therapeutics, Stem cells

Read Abstract +

More than 20% of all newborns admitted to the neonatal intensive care unit experience abnormally low platelet counts, called neonatal thrombocytopenia. Neonatal thrombocytopenia could increase a risk of hemorrhage, especially within the brain and adversely affect its development. No drugs or therapies are currently available for these sick newborns besides platelet transfusions. However, too many platelet transfusions could induce anti-platelet autoantibodies and other complications in some cases. One innovative idea for an alternative and non-invasive therapy for thrombocytopenia is low-level laser treatment (LLLT). LLLT is very safe, like blue-light-mediated treatment of newborn jaundice that has been used in clinics for decades with a long record of safety. LLLT stimulates the expression of a group of genes involved in mitochondrial generation in megakaryocytes (MKs) that are the precursor of platelets. This stimulation increases mitochondrial mass in MKs and enlarges the cells, which in turn elevates the rate of platelet production per MK. Our early investigation demonstrated that LLLT could quickly increase the number of circulating platelets and greatly reduce the risk of bleeding in thrombocytopenic adult animals. To explore a potential of this novel modality in management of neonatal thrombocytopenia, we investigated whether LLL could increase the platelet biogenesis in fetal liver and bone marrow MKs that intended to have low polyploidy compared to those MKs in adults. We found that LLL enhanced platelet production in MKs differentiated from fetal bone marrow and livers albeit at a slightly less efficiency. In addition to increased production of platelets from MKs, LLL appeared to increase the number of MKs differentiated from MK precursors in both bone marrow and liver of newborn mice in vivo as well, in contrast to little megakaryocytopoiesis induced by LLLT in adult mice. The ability of LLLT to increase not only platelet generation from MKs but also megakaryocytopoiesis in both livers and bone marrows in newborns suggests a potential for LLLT to manage neonatal thrombocytopenia and reduce the number of transfusions for thrombocytopenia-afflicted newborns.

Proceedings Article | 7 March 2019 Presentation + Paper

Synergistic inactivation of multidrug-resistant Pseudomonas aeruginosa by essential oil and blue light

Min Lu, Tianhong Dai, Mei Wu

Proceedings Volume 10863, 108630Z (2019) https://doi.org/10.1117/12.2507035

KEYWORDS: Bacteria, In vitro testing, Chemical analysis, Resistance, Luminescence, In vivo imaging, Microbiology, Bioluminescence, Skin

Read Abstract +

Proceedings Article | 8 February 2018 Presentation + Paper

Prolonging shelf-life of platelets by low-level laser

Qi Zhang, Min Lu, Mei Wu

Proceedings Volume 10477, 104770D (2018) https://doi.org/10.1117/12.2288414

KEYWORDS: Stem cells, Low level phototherapy, Photostimulation, Light emitting diodes, Near infrared, Plasma, Cell death, Photomedicine, Oxygen

Read Abstract +

Proceedings Article | 17 February 2017 Presentation + Paper

Low-level light treatment ameliorates immune thrombocytopenia

Jingke Yang, Qi Zhang, Mei Wu

Proceedings Volume 10048, 100480E (2017) https://doi.org/10.1117/12.2256303

KEYWORDS: Cell death, Plasma, Light emitting diodes, Acquisition tracking and pointing, Bone, Blood, Biological research, Pathology, In vivo imaging, Flow cytometry

Read Abstract +

Proceedings Article | 9 March 2015 Paper

Non-ablative fractional laser in conjunction with microneedle arrays for improved cutaneous vaccination

Ji Wang, Bo Li, Mei Wu

Proceedings Volume 9324, 932409 (2015) https://doi.org/10.1117/12.2079304

KEYWORDS: Skin, Manganese, Inflammation, Viruses, Injuries, Control systems, Lymphatic system, Blood, Tissues, Flow cytometry

Read Abstract +

Proceedings Article | 5 March 2015 Paper

Low level light in combination with metabolic modulators for effective therapy

Tingting Dong, Qi Zhang, Michael Hamblin, Mei Wu

Proceedings Volume 9309, 93090A (2015) https://doi.org/10.1117/12.2079363

KEYWORDS: Brain, Hypoxia, Traumatic brain injury, Acquisition tracking and pointing, Tissues, Cell death, Oxygen, Neurons, Glucose, Injuries

Read Abstract +

Proceedings Article | 13 July 2009 Paper

Anti-tumor immune response after photodynamic therapy

Pawel Mroz, Ana Castano, Mei Wu, Andrew Kung, Michael Hamblin

Proceedings Volume 7380, 73800F (2009) https://doi.org/10.1117/12.822994

KEYWORDS: Tumors, Photodynamic therapy, Lymphatic system, Proteins, Cancer, Colon, Tumor growth modeling, Molecules, Oncology, In vitro testing

Read Abstract +

Anti-tumor immunity is stimulated after PDT due a number of factors including: the acute inflammatory response caused by PDT, release of antigens from PDT-damaged tumor cells, priming of the adaptive immune system to recognize tumor-associated antigens (TAA), and induction of heat-shock proteins. The induction of specific CD8+ T-lymphocyte cells that recognize major histocompatibility complex class I (MHC-I) restricted epitopes of TAAs is a highly desirable goal in cancer therapy as it would allow the treatment of tumors that may have already metastasized. The PDT killed tumor cells may be phagocytosed by dendritic cells (DC) that then migrate to draining lymph nodes and prime naïve T-cells that recognize TAA epitopes. We have carried out in vivo PDT with a BPD-mediated vascular regimen using a pair of BALB/c mouse colon carcinomas: CT26 wild type expressing the naturally occurring retroviral antigen gp70 and CT26.CL25 additionally expressing beta-galactosidase (b-gal) as a model tumor rejection antigen. PDT of CT26.CL25 cured 100% of tumors but none of the CT26WT tumors (all recurred). Cured CT26.CL25 mice were resistant to rechallenge. Moreover mice with two bilateral CT26.CL25 tumors that had only one treated with PDT demonstrated spontaneous regression of 70% of untreated contralateral tumors. T-lymphocytes were isolated from lymph nodes of PDT cured mice that recognized a particular peptide specific to b-gal antigen. T-lymphocytes from LN were able to kill CT26.CL25 target cells in vitro but not CT26WT cells as shown by a chromium release assay. CT26.CL25 tumors treated with PDT and removed five days later had higher levels of Th1 cytokines than CT26 WT tumors showing a higher level of immune response. When mice bearing CT26WT tumors were treated with a regimen of low dose cyclophosphamide (CY) 2 days before, PDT led to 100% of cures (versus 0% without CY) and resistance to rechallenge. Low dose CY is thought to deplete regulatory T-cells (Treg, CD4+CD25+foxp3+) and potentiate immune response after PDT in the case of tumors that express self-antigens. These data suggest that PDT alone will stimulate a strong immune response when tumors express a robust antigen, and in cases where tumors express a self-antigen, T-reg depletion can unmask the immune response after PDT.

Proceedings Article | 13 February 2007 Paper

Photodynamic therapy stimulates anti-tumor immunity in a murine model

Pawel Mroz, Ana Castano, Mei Wu, Andrew Kung, Michael Hamblin

Proceedings Volume 6438, 643803 (2007) https://doi.org/10.1117/12.697630

KEYWORDS: Tumors, Photodynamic therapy, Cancer, Tumor growth modeling, Proteins, Oxygen, Colon, Computer programming, In vivo imaging, Potassium

Read Abstract +

Cancer is a leading cause of death among modern peoples largely due to metastatic disease. The ideal cancer treatment should target both the primary tumor and the metastases with the minimal toxicity. This is best accomplished by educating the body's immune system to recognize the tumor as foreign so that after the primary tumor is destroyed, distant metastases will also be eradicated. Photodynamic therapy (PDT) involves the IV administration of photosensitizers followed by illumination of the primary tumor with red light producing reactive oxygen species that cause vascular shutdown and tumor cell apoptosis. Anti-tumor immunity is stimulated after PDT due to the acute inflammatory response, priming of the immune system to recognize tumor-associated antigens (TAA), and induction of heat-shock proteins. The induction of specific CD8+ T lymphocyte cells that recognize major histocompatibility complex class I (MHC-I) restricted epitopes of TAAs is a highly desirable goal in cancer therapy. We here report on PDT of mice bearing tumors that either do or do not express an established TAA. We utilized a BALB/c colon adenocarcinoma cell line termed CT26.CL25 retrovirally transduced to stably express &bgr;-galactosidase ( &bgr;-gal, a bacterial protein), and its non-&bgr;-gal expressing wild-type counterpart termed CT26 WT, as well as the control cell line consisting of CT26 transduced with the empty retroviral vector termed CT26-neo. All cells expressed class I MHC restriction element H-2Ld syngenic to BALB/c mice. Vascular PDT with a regimen of 1mg/kg BPD injected IV, and 120 J/cm² of 690-nm laser light after 15 minutes successfully cured 100% of CT26.CL25 tumors but 0% of CT26-neo tumors and 0% of CT26 WT tumors. After 90 days tumor free interval the CT26.CL25 cured mice were rechallenged with CT26.CL25 tumor cells and 96% rejected the rechallenge while the CT26.CL25 cured mice did not reject a CT26 WT tumor cell challenge. Experiments with mice bearing two CT26.CL25 tumors (one in each leg) and only one tumor treated with PDT, showed that the immune response was strong enough to destroy an already established tumor in 70 of the mice and this effect was not seen with mice bearing two CT26 WT tumors. We expect these studies will lead to an understanding of the relevant determinants of immune response after PDT that could be rapidly applied to patient-selection and improvement in outcome for PDT for cancer.

Showing 5 of 13 publications

SPIE Conference Volume | 1 April 2024

Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2024

SPIE Conference Volume | 21 April 2023

Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2023

SPIE Conference Volume | 31 March 2022

Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic and Photobiomodulation Therapy XXX

SPIE Conference Volume | 28 March 2022

Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2022

SPIE Conference Volume | 23 April 2021

Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2021

Showing 5 of 7 publications

Conference Committee Involvement (16)

Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2025

25 January 2025 | San Francisco, California, United States

Mechanisms of Photobiomodulation Therapy XVIII

25 January 2025 | San Francisco, California, United States

Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2024

29 January 2024 | San Francisco, California, United States

Mechanisms of Photobiomodulation Therapy XVII

27 January 2024 | San Francisco, California, United States

Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2023

28 January 2023 | San Francisco, California, United States

Mechanisms of Photobiomodulation Therapy XVII

28 January 2023 | San Francisco, California, United States

Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2022

21 February 2022 | San Francisco, California, United States

Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic and Photobiomodulation Therapy XXX

22 January 2022 | San Francisco, California, United States

Mechanisms of Photobiomodulation Therapy XVI

6 March 2021 | Online Only, California, United States

Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2021

6 March 2021 | Online Only, California, United States

Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2020

3 February 2020 | San Francisco, California, United States

Mechanisms of Photobiomodulation Therapy XV

1 February 2020 | San Francisco, California, United States

Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2019

4 February 2019 | San Francisco, California, United States

Mechanisms of Photobiomodulation Therapy XIV

2 February 2019 | San Francisco, California, United States

Mechanisms of Photobiomodulation Therapy XIII

27 January 2018 | San Francisco, California, United States

Mechanisms of Photobiomodulation Therapy XII

28 January 2017 | San Francisco, California, United States

Showing 5 of 16 Conference Committees

Keywords/Phrases

Search In:

Publication Years